Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 1,584 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Diabetes Mellitus, Juvenile-Onset Clear all

Conditions: Diabetes Mellitus, Type 1
Interventions: No intervention; Other
Lead sponsor: Yale University; Other
Eligibility: 10 Years to 16 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Type 1 Diabetes Mellitus
Interventions: HOE901-U300 (Insulin Glargine 300 U/ml), Lantus (Insulin Glargine 100 U/ml), Mandated back ground therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 99
States / cities: Little Rock, Arkansas • Concord, California • Escondido, California + 80 more

Conditions: Type2 Diabetes, Type1diabetes, Insulin Dependent Diabetes
Interventions: No treatment; Device
Lead sponsor: Abbott Diabetes Care; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Walnut Creek, California • Rainier, Washington

Conditions: Diabetes Mellitus
Interventions: Metformin, Placebo; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 10 Years to 20 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Type 1 Diabetes
Interventions: MPC closed-loop system in insulin only mode, MPC closed-loop system in insulin/pramlintide mode; Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Type I Diabetes
Interventions: Capros; Dietary Supplement
Lead sponsor: Ohio State University; Other
Eligibility: 10 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Columbus, Ohio

Conditions: Type 1 Diabetes Mellitus, Maturity-Onset Diabetes of the Young, Type 2, MODY2, Insulin Resistance
Interventions: Hyperinsulinemic, euglycemic clamp, 20% dextrose; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 13 Years to 51 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: 4mm x 32G pen needle, 8mm x 31G pen needle, 5mm x 31G pen needle; Device
Lead sponsor: Becton, Dickinson and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 4
States / cities: Birmingham, Alabama • Escondido, California • Atlanta, Georgia + 1 more

Conditions: Type I Diabetes
Interventions: Exenatide (Bydureon®), Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 8
States / cities: San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 5 more

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: exercise; Other
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Type 1 Diabetes, Hypoglycemia Unawareness
Interventions: somatostatin; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Type 1 Diabetes, T1D Heart Failure, Cardio-renal Vascular Function and Failure, Diabetic Chronic Kidney Disease
Interventions: Finerenone, Sotagliflozin; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Portland, Oregon

Conditions: Diabetes Mellitus, Insulin-Dependent
Interventions: FreeStyle Navigator Continuous Glucose Monitoring System; Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 3 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 6
States / cities: Stanford, California • Aurora, Colorado • New Haven, Connecticut + 3 more

Conditions: Type 1 Diabetes Mellitus
Interventions: t:slim X2 with Control-IQ Technology & Dexcom G6 CGM, Control Group; Device
Lead sponsor: University of Virginia; Other
Eligibility: 6 Years to 13 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Stanford, California • Aurora, Colorado • New Haven, Connecticut + 1 more

Conditions: Diabetes Mellitus
Interventions: Not listed
Lead sponsor: DexCom, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Frexalimab, Placebo, Insulin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 14
States / cities: San Francisco, California • Aurora, Colorado • Gainesville, Florida + 11 more

Conditions: Diabetes Mellitus Type 1, Insomnia
Interventions: Sleep quality improvement therapy, Healthy Living; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 1 Diabetes Mellitus
Interventions: Artificial Pancreas Device; Device
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Type 1 Diabetes
Interventions: Co-transplantation of PTG with pancreatic islets; Combination Product
Lead sponsor: Peter Stock; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Multiple Model Predictive Controller; Device
Lead sponsor: Stanford University; Other
Eligibility: 21 Years to 45 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Stanford, California

Conditions: Type1diabetes
Interventions: Mixed Meal Tolerance Test; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 5 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Type 1 Diabetes Mellitus
Interventions: Vitamin C, Vitamin E; Dietary Supplement
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 8 Years to 15 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Type 1 Diabetes
Interventions: DiaPep277®; Drug
Lead sponsor: Andromeda Biotech Ltd.; Industry
Eligibility: 18 Years to 47 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Atlanta, Georgia • Detroit, Michigan • Asheville, North Carolina

Conditions: Type 1 Diabetes Mellitus
Interventions: Closed Loop Control (CLC), Open Loop; Device
Lead sponsor: University of Virginia; Other
Eligibility: 21 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Charlottesville, Virginia

Search by objective public record fields.

Sleep, Coping and Executive Functioning in Youth With Type 1 Diabetes

A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus

Accuracy Characterization Study

Adjunctive Metformin Therapy in Double Diabetes

Two Way Crossover Closed Loop Study Insulin vs Insulin and Pramlintide

Effects of Capros in Patients With Type-1 Diabetes

Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)

Comparison of Glycemic Control Among Diabetics Using Three Different Pen Needles

A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes

Exercise and Diabetes - an Observational Study of Exercise and Blood Glucose Control

Measurement of Glucose Metabolism in Humans Using Magnetic Resonance at 4 Tesla. Substudy: Hypoglycemia Unawareness

Precision T1D Platform - New Therapies for Cardio-Renal Complications

Pilot Study of the Navigator Continuous Glucose Monitor

A Study of t:Slim X2 With Control-IQ Technology

Effectiveness and Safety Study of the DexCom™ G4 Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes Mellitus

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)

CBTi for the Treatment of Insomnia in Type 1 Diabetes

Feasibility Evaluation of an Artificial Pancreas With Glucose Prediction Trust Index

Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Type 1 Diabetes

A Study to Evaluate a Multiple Model Probabilistic Predictive Controller (MMPPC) for Closed Loop Insulin Delivery

Development of Predictive Biomarkers

Effects of Vitamin C and E on Endothelial Function in Adolescent Diabetes

Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277®

Feasibility Study of a Modular Control to Range System in Type 1 Diabetes Mellitus